Dovato vs. Biktarvy

Reviewed on 11/12/2019

Are Dovato and Biktarvy the Same Thing?

Dovato (dolutegravir and lamivudine) and Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) are combinations of integrase strand transfer inhibitors (INSTIs) and nucleoside analogue reverse transcriptase inhibitors (NRTIs) used as complete regimens to treat human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of either drug.

Side effects of Dovato and Biktarvy that are similar include headache, diarrhea, nausea, insomnia, fatigue, and dizziness.

Side effects of Biktarvy that are different from Dovato include abnormal dreams.

Both Dovato and Biktarvy may interact with other antiretroviral medications, dofetilide, metformin, anticonvulsants, St. John's wort, certain antacids, and oral calcium and iron supplements (including multivitamins containing calcium or iron).

Dovato may also interact with rifampin, cation-containing laxatives, sucralfate, buffered medications, and sorbitol.

Biktarvy may also interact with antimycobacterials, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs).

What Are Possible Side Effects of Dovato?

Common side effects of Dovato include:

  • headache,
  • diarrhea,
  • nausea,
  • insomnia,
  • fatigue, and
  • dizziness

What Are Possible Side Effects of Biktarvy?

Common side effects of Biktarvy include:

  • diarrhea,
  • nausea,
  • headache,
  • fatigue,
  • abnormal dreams,
  • dizziness, and
  • insomnia

What Is Dovato?

Dovato (dolutegravir and lamivudine) is a combination of an integrase strand transfer inhibitor (INSTI) and a nucleoside analogue reverse transcriptase inhibitor (NRTI) indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of Dovato.

What Is Biktarvy?

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) is a three-drug combination of a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), and two HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy.

SLIDESHOW

A Timeline of the HIV/AIDS Pandemic See Slideshow

What Drugs Interact With Dovato?

Dovato may interact with other antiretroviral drugs for the treatment of HIV-1 infection, dofetilide, metformin, anticonvulsants, rifampin, St. John's wort, cation-containing antacids or laxatives, sucralfate, buffered medications, oral calcium and iron supplements (including multivitamins containing calcium or iron), and sorbitol.

What Drugs Interact With Biktarvy?

Biktarvy may interact with other antiretroviral medications, dofetilide, anticonvulsants, antimycobacterials, St John's wort, antacids containing aluminum or magnesium, supplements containing calcium or iron, metformin, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple nonsteroidal anti-inflammatory drugs (NSAIDs). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Biktarvy; it is unknown how it would affect a fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Biktarvy during pregnancy. Because of the potential for HIV transmission, breastfeeding while using Biktarvy is not recommended.

How Should Dovato Be Taken?

The dose of Dovato is one tablet taken orally once daily with or without food.

How Should Biktarvy Be Taken?

Biktarvy is a three-drug fixed dose combination product containing 50 mg of bictegravir (BIC), 200 mg of emtricitabine (FTC), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of Biktarvy is one tablet taken once daily with or without food.

QUESTION

What is HIV? See Answer
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
ViiV Healthcare. Dovato Product Monograph.

https://www.dovato.com

Gilead. Biktarvy Product Information.

https://www.biktarvy.com

Health Solutions From Our Sponsors